{"entity":{"id":"nct05691491","kind":"trial","name":"Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness","aka":[],"tldr":"A phase 1/2 trial of temozolomide in colorectal cancer, run by National Cancer Institute (NCI), now recruiting.","summary":"Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness is a phase 1/2, interventional study registered as NCT05691491 by National Cancer Institute (NCI), with a registry enrolment figure of 42 participants, started 2023-09-28 and due to reach its primary completion in 2027-03-01. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Temozolomide; Tuvusertib. Conditions listed: Advanced Malignant Solid Neoplasm; Advanced Microsatellite Stable Colorectal Carcinoma; Hematopoietic and Lymphatic System Neoplasm; Metastatic Malignant Solid Neoplasm; Metastatic Microsatellite Stable Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8. Primary outcome: Dose limiting toxicity and the maximum tolerated dose. Colorectal eligibility wording from the registry: \"Patients with MGMT promoter hypermethylated colorectal cancer must be mismatch repair proficient / microsatellite stable\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05691491","url":"https://clinicaltrials.gov/study/NCT05691491"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05691491","phase":"1/2","setting":"A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774","sponsor":"National Cancer Institute (NCI)","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05691491/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}